Table 1.
Clinical characteristics of patients with prostate cancer from whom samples of bone metastases were analyzed by Infinium Methylation EPIC arrays
| Clinical characteristics | Hormone-naíve n = 14 |
Short-term castrateda n = 4 |
Castration-resistantb n = 52 |
|---|---|---|---|
| Age at diagnosis (years) | 78 (74–80) | 75 (72–76) | 71 (64–75) |
| Age at metastasis surgery (years) | – | – | 73 (68–80) |
| Serum PSA at diagnosis (ng/ml) | 320 (82–980) | 2300 (560–4300) | 82 (40–510) |
| Serum PSA at metastasis surgery (ng/ml) | – | – | 250 (82–630) |
| Bicalutamide prior to metastasis surgeryc | |||
| Yes | 0 | 0 | 28 |
| No | 14 | 4 | 24 |
| Radiation prior to metastasis surgeryd | |||
| Yes | 0 | 0 | 7 |
| No | 14 | 4 | 45 |
| Chemotherapy prior to metastasis surgery | |||
| Yes | 0 | 0 | 9 |
| No | 14 | 4 | 43 |
| Ra-223 prior to metastasis surgery | |||
| Yes | 0 | 0 | 6 |
| No | 14 | 4 | 46 |
Continuous values are given as median (25th; 75th percentiles)
aShort-term treated patients had received androgen ablation therapy for 1–3 days before metastasis surgery
bCastration-resistant patients had disease progression after long-term androgen deprivation therapy. First line androgen-deprivation therapy (ADT) includes surgical ablation, LHRH/GNRH agonist therapy, and therapy with anti-androgens
cCastration therapy as stated above and bicalutamide for treatment of CRPC
dRadiation towards operation site